WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ: ACUS) today reported financial results for the third quarter ended September 30, 2007 and commented on its business and progress. The Company is moving aggressively to file its planned New Drug Application (NDA) submission for its lead product candidate, ImagifyTM (Perflubutane Polymer Microspheres) for Injectable Suspension, which is planned for early in 2008. Imagify is a Perfusion Stress Echo imaging agent for use in detecting coronary artery disease.
